The Global Infection Control Market is Set to Grow as the U.S. Population Ages

NEW YORK, November 2, 2018 /PRNewswire/ --

According to MarketsandMarkets, the global infection control market is expected to reach USD 21.06 Billion by 2022, after having grown from USD 15.35 Billion in 2017. The market is also expected to have a CAGR of 6.5%. The research indicates that the increasing use of e-beam sterilization, the rising importance of single-use medical nonwovens and medical devices are increasing the demand for disinfection and sterilization products and services. Based on end user, the global infection control market is segmented into hospitals & clinics, medical devices companies, food industry, life sciences industry, pharmaceutical companies as well as other end users. Hospitals & clinics are currently projected to register the highest CAGR during the forecast period. PCT Ltd. (OTC: PCTL), MEDNAX, Inc. (NYSE: MD), Owens & Minor, Inc. (NYSE: OMI), CytoSorbents Corporation (NASDAQ: CTSO), Cerus Corporation (NASDAQ: CERS)

Research by Future Market Insights indicates that according to the U.S. Department of Health and Human Services, it is estimated that one in every 20 infections are hospital-acquired diseases in the U.S. Similarly, improving the reimbursement scenarios, regarding infection control in various nations such as U.S., Japan and U.K., will further propel the growth of the infection control market. Likewise, an aging population will also augment the growth of the market. It has been estimated by the World Health Organization (WHO) that the global elderly population is expected to reach around 2 billion by 2050, having been around 524 million in 2010.

PCT Ltd. (OTC: PCTL) announced breaking news after the market close yesterday that, "with its New York-based representative, it has entered into a contractual agreement for the installation and operation of two Annihilyzer® Infection Control Systems in a major Brooklyn hospital. Installation of the systems is currently underway and near completion.

The Annihilyzer® Infection Control System is designed to prevent and reduce the occurrence of costly and often difficult to treat hospital-associated infections (HAI's).

According to the Center for Disease Control & Prevention (CDC), 'On any given day, about one in 25 hospital patients has at least one healthcare associated infection.' Quoted in Clinical Leadership & Infection Control, Lynn White, MD, president of Patient Shield Concepts, said '…the estimated direct medical cost of HAIs is around $10 billion annually, not including cost-shifting to private payers. Including cost-shifting, HAIs may cost closer to between $35 billion and $45 billion for acute-care hospitals annually. The total direct, indirect and nonmedical social costs of HAIs are estimated at around $96 billion to $147 billion annually, including loss of work, legal costs and other patient factors.'

The Annihilyzer® Infection Control System produces on-site generated Electrochemically Activated cleaner and disinfectant fluid solutions that allow hospitals to move away from traditional disinfectants that are toxic and can cause harm to the housekeeping staff and patients. The Annihilyzer Infection Control System produces a cleaner and a disinfectant that are safe, environmentally sound and greatly reduce the damage to furnishings and equipment caused by toxic chemicals, yet is effective against HAI's like MRSA, VRE and C-diff. PCT Health's system tracks the life cycle of the cleaner and disinfectant and alerts the user before the product is no longer at its optimum effectiveness.

The Annihilyzer® Fluid Tracking System can be customized to track employees to ensure that all proper cleaning and disinfecting protocols are being performed during the cleaning process. This assists the hospital administration by supplying valuable data regarding the who, what, when and how all areas of the hospital are cleaned and disinfected.

The Annihilyzer® System also incorporates the use of Electrostatic Smart Applicators that apply disinfectant to all surfaces. Human error associated with improper application and coverage of disinfectant is no longer an issue as the electrostatic applicators ensure that all surfaces are covered and wrapped with disinfectant. Fogging or misting systems are not time or cost effective whereas the electrostatic application process is more thorough and takes less time, so room turnover is much faster. The Annihilyzer® Infection Control System is very cost effective and performs well where other cleaning and disinfecting systems sometimes fail.

For additional information about the Annihilyzer® Infection Control System, visit

MEDNAX, Inc. (NYSE: MD) is a national health solutions partner based in Sunrise, Fla. And is comprised of the nation's leading providers of physician services. MEDNAX, Inc. recently announced that it has partnered with Pacira Pharmaceuticals, Inc. to address the ongoing use of opioids during, and after, cesarean surgery by launching a national collaborative aimed at addressing the Quadruple Aim through the implementation of an Enhanced Recovery after Cesarean Surgery (ERACS™) program. The collaborative will be multi-disciplinary in nature, engaging the expertise of maternal-fetal medicine physicians, anesthesiologists, obstetricians and perioperative nurses to improve the patient experience as well as maternal and infant health, reduce the total cost of care and enhance provider satisfaction. The ERACS™ program will encompass comprehensive educational and clinical implementation pathways. The overarching goals will be to educate clinical teams, shorten the length of postoperative hospital stays, reduce the use of opioid analgesics and improve postoperative pain control. In addition, MEDNAX and Pacira will monitor a series of clinical quality, safety and value-based performance indicators including: reduced serious maternal and infant morbidity, reduced postoperative nausea and vomiting, lower rate of surgical site infections, lower rate of return to the operating room, lower rate of readmission to the hospital and lower total cost of care.

Owens & Minor, Inc. (NYSE: OMI) is a global healthcare solutions company with integrated technologies, products, and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care. Owens & Minor announced earlier this year that it had completed the acquisition of the surgical and infection prevention ("S&IP") business of Halyard Health, Inc., on April 30th, 2018, for approximately USD 710 Million in cash, subject to certain adjustments as provided in the Amended and Restated Purchase Agreement. With the acquisition of the Halyard S&IP business, a recognized leader in its segment, Owens & Minor takes a significant step in transforming its business into a global healthcare solutions provider. This transaction expands Owens & Minor's reach into new markets around the world, develops its presence in the medical products segment, and opens new channels for growth. The acquisition will also add greater scale to Owens & Minor's existing own-brand product portfolio and help to expand the company's addressable markets.

CytoSorbents Corporation (NASDAQ: CTSO) is a leader in critical care immunotherapy, specializing in blood purification. Recently, CytoSorbents once again sponsored the 7th Annual Celebration of Sepsis Heroes event hosted by the Sepsis Alliance on September 13th, 2018, in New York City at Marquee New York (289 10th Avenue). The sold-out event recognizes individuals and organizations that are making a difference in sepsis awareness. This year's honorees include Mr. Jay Towers, the University of Michigan Post ICU Longitudinal Survivor Experience (UM-PULSE), Rooks County Health Center, Ms. Jill Kogan Blake, and Ms. Sharon Hansen. In addition, CytoSorbents will again sponsor the Roger Bone Award for Excellence in Sepsis Research, to be awarded by the German Sepsis Society at this year's DIVI Critical Care Congress in Leipzig, Germany, to recognize an outstanding publication in clinical sepsis research for young scientists in German-speaking countries. Dr. Bone was a pioneer in understanding the connection between uncontrolled inflammation and organ failure in sepsis pathology and one of the fathers of critical care immunotherapy. Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, "Sepsis is the overzealous immune response to an infection, and remains one of the top ten causes of death worldwide, despite the use of antibiotics and standard medical care. Only through a coordinated effort of infection prevention, faster recognition, early antibiotic treatment, and aggressive control of deadly inflammation, can we turn the tide on this lethal scourge. We are thankful that our CytoSorb therapy is being increasingly embraced around the world as a powerful new weapon against sepsis."

Cerus Corporation (NASDAQ: CERS) is a biomedical products company focused in the field of blood transfusion safety. Cerus Corporation recently announced that the U.S. Department of the Navy will implement pathogen-reduction for all apheresis platelets collected at Navy Blood Donor Centers. The Bureau of Medicine and Surgery (BUMED) noted that with the recent history with Zika Virus, Ebola, Chikungunya, Dengue, and Babesia, emerging pathogens continue to threaten the blood supply and that the use of pathogen reduction technologies will preemptively address the risk due to emerging pathogens. All Navy Blood Donor Centers are required to implement the policy to pathogen-reduce platelet components by December 31st, 2018. "We are pleased that the U.S. Navy is expanding the use of pathogen-reduction technology to treat platelet components throughout its entire blood collection system," said William 'Obi' Greenman, Cerus' President and Chief Executive Officer. "By fully adopting pathogen reduction, the U.S Navy Blood Program is providing our Nation's Sailors, Marines, and their families around the globe access to platelets with reduced risk of transfusion-transmitted infection (TTI) from known and emerging pathogens."

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For pct ltd. financial and corporate news dissemination, has been compensated five thousand dollars by paradigm convergence. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit:

For further information:



Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.